Loading...
XNAS
GDTC
Market cap25mUSD
Jun 10, Last price  
2.05USD
1D
-1.68%
1Q
-21.15%
IPO
-45.48%
Name

CytoMed Therapeutics Ltd

Chart & Performance

D1W1MN
P/E
P/S
113.90
EPS
Div Yield, %
Shrs. gr., 5y
Rev. gr., 5y
%
Revenues
291k
-20.16%
059,468113,841363,912290,560
Net income
-3m
L-2.98%
-632,611-1,942,242-2,074,531-3,227,956-3,131,788
CFO
-3m
L+85.25%
-471,847-849,443-1,712,985-1,398,409-2,590,580

Profile

CytoMed Therapeutics Limited, a pre-clinical biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers. The company's lead product candidate is CTM-N2D, which consists of expanded gamma delta T cells grafted with natural killer group 2D ligands-targeting chimeric antigen receptor to improve anti-cancer cytotoxicity. It is also developing iPSC-gdNKT, which utilizes iPSC as a starting material to generate gdNKT, a synthetic hybrid of a gamma delta T cell and a NK cell; and CTM-GDT, a product candidate that consists of expanded gamma delta T cells, and exploits the multiple recognition system of gamma delta T cell to recognize and treat a range of cancers. The company was incorporated in 2018 and is headquartered in Singapore.
IPO date
Apr 14, 2023
Employees
Domiciled in
SG
Incorporated in
SG

Valuation

Title
SGD in thousands, except ratios and share amounts
FYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑12
Income
Revenues
291
-20.16%
364
219.67%
Cost of revenue
1,652
2,128
Unusual Expense (Income)
NOPBT
(1,361)
(1,764)
NOPBT Margin
Operating Taxes
2
Tax Rate
NOPAT
(1,361)
(1,766)
Net income
(3,132)
-2.98%
(3,228)
55.60%
Dividends
Dividend yield
Proceeds from repurchase of equity
11,307
1,223
BB yield
-21.71%
Debt
Debt current
40
3,744
Long-term debt
414
490
Deferred revenue
Other long-term liabilities
Net debt
(8,689)
2,415
Cash flow
Cash from operating activities
(2,591)
(1,398)
CAPEX
(474)
Cash from investing activities
(473)
Cash from financing activities
8,275
969
FCF
(342)
(1,753)
Balance
Cash
8,995
1,580
Long term investments
148
239
Excess cash
9,128
1,801
Stockholders' equity
8,525
714
Invested Capital
3,167
4,090
ROIC
ROCE
EV
Common stock shares outstanding
10,630
7,915
Price
4.90
 
Market cap
52,089
 
EV
43,400
EBITDA
(1,073)
(1,371)
EV/EBITDA
Interest
125
Interest/NOPBT